Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

BSGI is found to be sensitive to early stage breast cancer

Dilon Technologies : 30 May, 2008  (Company News)
Breast-Specific Gamma Imaging (BSGI) is highly sensitive in detecting the presence of cancer according to researchers at The George Washington University Medical Center in Washington, DC, USA.
The researchers determined that BSGI was a useful detection tool and that it was as sensitive as MRI for most cancers and perhaps more sensitive for ductal carcinoma in-situ, an early stage of breast cancer. The study is reported in an article in the June 2008 issue of Radiology.

BSGI, molecular imaging of the breast utilising a Dilon high-resolution, small-field-of-view gamma camera, is an increasingly utilised adjunct imaging modality for the diagnosis of breast cancer. Initial studies with this imaging technique report sensitivities similar to MRI with a higher specificity - which is the ability of a test to show when disease is not present.

In the retrospective study, 146 women underwent BSGI and breast biopsy. Study images were assigned scores, and scores were classified as positive or negative and compared with biopsy results. BSGI helped detect cancer in 96.4 percent of the noted malignant lesions; the positive predictive value was 68.8 percent, specificity of 59.5 percent and the negative predictive value for nonmalignant lesions was 94.3 percent. The smallest invasive cancer and DCIS detected were both 1mm, and BSGI helped detect occult cancer not visualised at mammography or ultrasonography in six patients.

Mammography remains the imaging modality of choice for breast cancer screening. The overall sensitivity of mammography has been reported to be 78 to 85 percent; however, the sensitivity of mammography decreases to 42 to 68 percent in women with dense breasts. In addition, the false-positive rate of screening mammography is 15 to 30 percent, leading to many benign findings at biopsy. Limitations in the sensitivity and specificity of screening mammography led to the investigation of adjunct breast imaging modalities; specifically BSGI, which provides physiological data not obtained with the anatomic imaging techniques of mammography and ultrasound.

'Our study supports the use of BSGI because MR imaging would be used in clinical practice with equal sensitivity and higher specificity. An advantage of BSGI is the greater comfort of the patient, with the study being performed with the patient sitting as opposed to being placed in an MR imager. Additionally, BSGI results in four to eight images as compared with several hundred images in a breast MR examination, leading to a associated decrease in interpretation time. In our practice, BSGI has been integrated in the daily evaluation of patients, as appropriate,' said Dr Rachel Brem of The George Washington University Medical Center.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo